Baricitinib, a selective and reversible inhibitor of the Janus kinases JAK1 and JAK2, previously approved for the treatment of rheumatoid arthritis [1], has been recently licensed for the treatment of severe Coronavirus disease 2019 (COVID-19) (COVID-19 Treatment Guidelines Panel. The gene discussed is JAK1; the disease is rheumatoid arthritis.